Stocks:
5,472
ETFs:
2,400
Exchanges:
11
Market Cap:
$58.99T
24h Vol:
$9.86B
Dominance:
MSFT:5.13%
Stocklytics Platform
BETA
Instrument logo  AMLX

Amylyx Pharmaceuticals, Inc.

AMLX
62 / 100
$19.00arrow_drop_up8.20%$1.44
Key Stats
Open$17.90
Prev. Close$17.56
EPS0.7
DividendNon-Dividend
Next Earnings Date-
Dividend Yield %-
Market Cap$1.28B
PE Ratio27.14
LOWHIGH
Day Range17.90
19.02
52 Week Range11.82
38.32
Ratios
P/B Ratio2.76
Revenue$380.78M
Operating M. %1.78%
Earnings$49.27M
Earnings Growth %124.84%
EBITDA Margin %10.48%
ROE %12.73%
EPS0.7
Fundamentals
RPS$5.66
Gross Profit$355.34M
EBITDA$39.89M
Total Debt$4.23M
P/S Ratio3.1x
Enterprise to EBITDA20.79
Profit Margin12.94%
ROA5.34%
Debt/Equity Ratio0.01%
Payout Ratio-
Industry average yield3.02%
Last Dividend pay date-
Dividend per share-
Dividend yield forecast-

Stock Analysis

Technicals

Summarizing what the indicators are suggesting.

Strong Buy
Buy
Neutral
Sell
Strong Sell
Analyst rating

An aggregate view of professional's ratings.

Strong Buy
Buy
Neutral
Sell
Strong Sell

Stock Performance

AMLXarrow_drop_up8.20%
US Healthcare Sectorarrow_drop_up1.17%
US Marketarrow_drop_up0.46%
AMLX / Market
AMLX exceeded the US Market which returned 0.46% over the last twenty four hours.
AMLX / Healthcare Sector
AMLX exceeded the US Healthcare sector which returned 1.17% over the last twenty four hours.

Amylyx Pharmaceuticals, Inc. (AMLX) Statistics

Amylyx Pharmaceuticals, Inc. (AMLX) is a biopharmaceutical company focused on developing treatments for neurodegenerative diseases. As of the latest statistics, the stock has shown promising performance in the market. With a strong valuation, Amylyx Pharmaceuticals has attracted investor attention. The company's fundamentals also reflect its potential for growth. With a high stock revenue per share, Amylyx Pharmaceuticals demonstrates its ability to generate revenue efficiently. Moreover, its Enterprise to EBITDA ratio suggests a healthy financial position. The company has also managed to maintain a favorable profit margin, indicating efficient cost management. In terms of debt, Amylyx Pharmaceuticals has not accumulated a significant amount, which bodes well for its financial stability. Additionally, the company's gross profit is notable, highlighting its ability to generate profits from its operations.

Amylyx Pharmaceuticals, Inc. (AMLX) operates under the leadership of its CEO, whose name has not been provided. The CEO plays a crucial role in guiding the company towards its goals and ensuring its success. With their expertise and strategic decision-making, the CEO of Amylyx Pharmaceuticals drives the company forward in its mission to develop treatments for neurodegenerative diseases. With a focus on innovation and scientific advancements, Amylyx Pharmaceuticals aims to make a meaningful impact in the field of neurodegenerative diseases. By creating value for both patients and shareholders, the company strives to improve the lives of individuals affected by these debilitating conditions. With a strong foundation and a dedicated CEO at the helm, Amylyx Pharmaceuticals is poised for future success.

add Amylyx Pharmaceuticals, Inc. to watchlist

Keep an eye on Amylyx Pharmaceuticals, Inc.

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

search
question_mark
How has Amylyx Pharmaceuticals, Inc. (AMLX) stock's performance compared to its sector and the market over the past year?

Over the past year, Amylyx Pharmaceuticals, Inc. (AMLX) has experienced a price change of -43.54%. Compared to the Healthcare sector, which saw a change of 33.58%, Amylyx Pharmaceuticals, Inc. has underperformed compared to its sector, indicating its relative standing within the Healthcare sector. Against the broader market's change of 40.25%, it has fallen short of the market average. This comparison highlights Amylyx Pharmaceuticals, Inc.'s performance relative to both its sector and the overall market over the last year.

question_mark
What is the PE ratio of Amylyx Pharmaceuticals, Inc. (AMLX) stock?

The PE (Price to Earnings) ratio of Amylyx Pharmaceuticals, Inc. (AMLX) is currently 27.14. This metric is used to evaluate the valuation of a company's stock, comparing its current share price relative to its per-share earnings.

question_mark
What is the EPS of Amylyx Pharmaceuticals, Inc. (AMLX) stock?

The Earnings Per Share (EPS) for Amylyx Pharmaceuticals, Inc. (AMLX), calculated on a diluted basis, is $0.7. EPS is a key indicator of a company's profitability, showing the portion of a company's profit allocated to each outstanding share of common stock.

question_mark
What is the operating margin of Amylyx Pharmaceuticals, Inc. (AMLX) stock?

The operating margin for Amylyx Pharmaceuticals, Inc. (AMLX) is 1.78%. This metric represents the percentage of revenue that remains after paying for variable production costs, indicating the efficiency and profitability of the company's core business operations.

question_mark
What is the EBITDA of Amylyx Pharmaceuticals, Inc. (AMLX) stock?

The EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) of Amylyx Pharmaceuticals, Inc. (AMLX) is $39.89M. EBITDA is a widely used earnings metric to assess a company's operational efficiency and profitability before the impact of non-operating decisions such as financing, accounting, and tax environments.

question_mark
How much debt does Amylyx Pharmaceuticals, Inc. (AMLX) have?

Amylyx Pharmaceuticals, Inc. (AMLX) has a total debt of $4.24M. The net debt, which accounts for cash and cash equivalents against the total debt, is -$165.96M.

email

Sign up for our newsletter

Join our exclusive community of over one million investment enthusiasts and receive our free newsletter filled with analysis, news, and updates every weekday.

Approach investments with caution like a driver who slows down on a curvy road.